MEI Pharma price target raised to $15 from $11 at Stifel Stifel raised its price target on MEI as the firm thinks that the company reported positive data for a trial of its ME-344 drug in patients with refractory solid tumors. The firm reports that five of 21 patients demonstrated prolonged progression free survival of at least twice the duration of the immediate prior therapy. Stifel keeps a Buy rating on the stock.
News For MEIP From The Last 14 Days
Check below for free stories on MEIP the last two weeks.